1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Johnson Chemical Pharmaceutical Works Co., Ltd.

Johnson Chemical Pharmaceutical Works Co., Ltd.

TTPEX:4747
23.20
TWD
0.00
(0.00%)
0.98EPS
24.63P/E
2.22BMarket Cap
Johnson Chemical Pharmaceutical Works Co., Ltd.
TPEX:4747
(Taipei Exchange)

Recent

price

23.20

P/E

ratio

24.63

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
3.86
4.7
5.1
6.22
6.36
5.83
5.92
5.96
6.22
6.42
6.4
6.21
7.47
8.52
6.81
6.32
6.4
Revenue per Share
0.43
0.75
1.01
1.31
1.26
0.95
0.96
0.91
0.86
0.97
0.96
0.74
0.98
1.12
0.94
0.59
0.99
Basic EPS, GAAP
0.43
0.69
0.32
0.97
1.23
0.56
-0.41
0.55
0.92
0.85
-1.37
0.23
0.45
1.46
0.55
0.08
-0.45
Free Cash Flow per Basic Share
0.19
0.2
0.29
0.41
0.4
0.99
0.79
0.86
0.82
0.75
0.82
0.87
0.66
0.84
0.75
0.87
- -
Dividend per Share
6.22
6.68
7.22
9.86
11.15
12.4
12.57
12.61
12.63
12.8
12.96
12.81
13.16
19.14
18.96
18.83
19.12
Book Value per Share
6.22
6.68
7.15
9.86
11.15
12.4
12.57
12.61
12.63
12.67
12.85
12.72
13.1
19.11
18.95
18.83
19.12
Tangible Book Value per Share
52
52
52
50
57
65
66
66
66
66
66
66
66
71
90
90
90
Basic Weighted Avg Shares
201
245
266
314
362
380
392
395
412
425
424
411
495
607
611
570
578
Sales/Revenue/Turnover
14.19
18.9
19.88
25.14
22.92
18.74
18.49
16.83
16.7
18.55
17.81
15.14
16.71
16.3
16.03
12.83
10.24
Operating Margin (%)
7
8
9
10
10
10
10
10
10
12
13
15
18
21
21
20
20
Depreciation Expense
23
39
53
66
72
62
63
60
57
64
64
49
65
80
84
54
89
Net Income, GAAP
20.03
16.96
16.07
16.86
16.58
16.87
14.84
16.54
19.21
20.84
16.97
20.73
20.46
21
22.62
15.58
4.62
Effective Tax Rate (%)
11.27
16.05
19.79
20.98
19.76
16.34
16.17
15.21
13.91
15.16
14.99
11.93
13.11
13.14
13.76
9.39
15.47
Profit Margin (%)
161
176
205
388
418
527
443
443
443
444
305
268
247
1,139
1,166
1,073
-217
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
101
90
- -
- -
LT Debt
324
349
377
584
635
822
832
835
837
848
858
848
872
1,672
1,704
1,709
1,738
Total Equity
7.1
11.12
11.54
13.44
11.2
8.06
7.43
6.6
6.59
7.33
6.81
5.1
6.89
5.57
4.09
3.23
2.67
Return on Invested Capital (%)
7.13
11.69
14.52
13.7
11.74
8.53
7.67
7.2
6.85
7.66
6.99
5.21
7.06
6.03
4.71
2.96
4.77
Return on Capital (%)
7.13
11.69
14.52
13.7
11.74
8.53
7.67
7.2
6.85
7.65
7.45
5.75
7.54
6.27
4.98
3.14
5.25
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
261
1,181
645
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
91
91
91
Market Capitalization
2,687
2,459
2,216

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,457
1,368
603
Cash, Cash Equivalents & STI
1,152
1,027
262
Accounts Receivable, Net
98
111
109
Inventories
188
207
213
Total Current Liabilities
384
1,311
820
Payables & Accruals
- -
- -
- -
ST Debt
261
1,181
645
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10%
19.13%
0.33%
Free Cash Flow
-51.49%
18.41%
-84.58%
Net Income, GAAP
0.47%
0.28%
-36.4%
Sales/Revenue/Turnover
4.5%
6.78%
-6.81%
Total Cash Common Dividend
3.45%
9.81%
16.8%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
163
150
150
148
611
2025
147
138
134
151
570
2026
147
147
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.23
0.25
0.24
0.22
0.94
2025
0.24
0.22
0.18
-0.03
0.59
2026
0.73
0.12
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.75
2025
- -
- -
- -
- -
0.87
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Johnson Chemical Pharmaceutical Works Co., Ltd. (4747.TWO) manufactures, imports, and sells pharmaceutical ingredients, raw materials, and finished products primarily in Taiwan and other Asian markets. The company offers a broad range of therapeutics covering the central nervous system, respiratory system, cardiovascular system, gastrointestinal tract, endocrine system, vitamins, anti-inflammatory agents, cough and cold remedies, and pain relievers; its products are provided in solid dosage forms including soft and hard capsules, sugar-coated and film-coated tablets, uncoated tablets, powders, granules, suppositories, and nasal sprays. Founded in 1959 by Mr. Johnson Huang and headquartered at No. 77, Sec. 4, San Ho Road, Sanchung District, New Taipei City, Taiwan, the company operates manufacturing facilities in New Taipei City and Yilan County, employs approximately 171 people, and maintains PIC/S GMP certification from the Taiwan Food and Drug Administration. Recent developments include the 2019 reinvestment in subsidiary Pei Jin International Co., Ltd., land acquisitions in Sanchong District in 2020 and previously in Yilan County in 2015 to support operational expansion, and a capital increase leading to its 2013 IPO listing on the Taipei Exchange; in 2025, the company reported nine-month sales of TWD 419.24 million and continues collaborations with research institutes and academia for new generics and Class II new drugs.